Expertise in
4
conditions

Bernadette Eberlein

Biedersteiner Str. 29, 
Munich, BY, DE 
Expertise in
4
conditions
Biedersteiner Str. 29, 
Munich, BY, DE 
OverviewLocationsClinical Research

Overview

Bernadette Eberlein practices in Munich, Germany. Ms. Eberlein is highly rated in 4 conditions, according to our data. Her top areas of expertise are Alpha-gal Syndrome (AGS), Anaphylaxis, Polymorphous Light Eruption, and Grass Allergy.

Her clinical research consists of co-authoring 88 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

Biedersteiner Str. 29, Munich, BY 80802, Germany
Other Locations
Liesel Beckmann Str. 1, Freising, BY 85354, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
View 1 Less Clinical Trial

88 Total Publications

Component-Resolved IgE and IgG4 Profiling Reveals Robust IgG4 Responses Primarily to Abundant Hymenoptera Allergens During Venom Immunotherapy and in Beekeepers.
Component-Resolved IgE and IgG4 Profiling Reveals Robust IgG4 Responses Primarily to Abundant Hymenoptera Allergens During Venom Immunotherapy and in Beekeepers.
Journal: Journal of investigational allergology & clinical immunology
Published: May 30, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Eberlein's expertise for a condition
ConditionClose
      View All 19 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile